Redeye: Episurf Medical Q2 - Total focus on the US
Redeye provides a more in-depth review of Episurf Medical’s Q2 report. Since the company’s sales came in lower than expected, we made some downward adjustments to our estimates for the short and medium-term sales forecasts. We revise our base case valuation to SEK1.3 (SEK1.4) per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/